The federal Food and Drug Administration October 3 approved a new daily PrEP pill that could offer a safer option for some individuals at risk for HIV, but the indication does not cover everyone who ...

A new HIV prevention option works well for gay and bisexual men and transgender women and should be approved by the Food and Drug Administration for these populations, according to an expert advisory ...

(Reuters) - An FDA advisory panel on Wednesday voted in favour of Gilead Sciences Inc's combination drug to reduce the risk of sexually acquired HIV infection in men and transgender women who have sex ...

Adolescents, young women, and those in the South may face greater challenges getting PrEP ...

As Gilead Sciences tussles with a web of HIV drug litigation, a high-stakes case tied to patents for prevention medicines is coming back to test the drugmaker. On Friday, the U.S. Department of ...

In it, the safety and efficacy of a twice-yearly, under-the-skin (subcutaneous) injection of lenacapavir for PrEP was compared with once-daily oral Descovy or Truvada in more than 5,300 cisgender ...

The Biden-Harris administration announced Monday a new requirement for insurance providers to cover injectable PrEP in their policies without a co-payment for consumers. The new rule, built on ...

In June, Gilead Sciences announced impressive early results from its PURPOSE 1 trial, which showed 100 percent efficacy of lenacapavir in preventing new HIV infections among cisgender women in ...

Add Yahoo as a preferred source to see more of our stories on Google. a group of fit men in blue and white outfits promote national prep day Today is the first National PrEP Day — a new annual event ...